Yokogawa Insilico Biotechnology

Yokogawa Insilico Biotechnology is a Germany-based bioprocess software and services company focused on digital twin technology for biopharmaceutical development and manufacturing. The company develops predictive models that combine mechanistic intracellular metabolic network models with data-driven and machine-learning approaches to optimize cell culture, clone selection, media and feeding strategies, process scale-up, and manufacturing control. Its offerings are used by biopharma companies to reduce wet-lab experimentation, improve productivity, stabilize product quality, and accelerate time to market. Originally founded as Insilico Biotechnology, the company was acquired by Yokogawa Electric in 2021 and now operates as a Yokogawa group company. Rather than developing therapeutic drug assets, it commercializes a computational and bioprocess optimization platform for smart biomanufacturing.